Pulmonology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

KL4-Surfactant (Lucinactant) Protects Human Airway Epithelium from Hyperoxia
Pediatric Research, 08/01/08

Yan Z et al. - This study tested whether Lucinactant reduces markers of inflammation, damage and remodeling in human airway epithelial cells exposed to hyperoxia. Calu-3 monolayers cultured at an air-liquid interface were treated apically with 140 [mu]L of normal saline, Lucinactant or Beractant. Treated monolayers were exposed to 60% O2/5% CO2 for 24 or 72 h. Transepithelial resistance and cell viability were greater in both surfactant groups compared with saline; by 72 h Lucinactant cells had greater TER than Beractant. Surfactant treated groups secreted less IL-8 than saline, whereas Lucinactant cells secreted less IL-6 than saline and Beractant. Matrix metalloproteinase 7, expressed by saline and Beractant treated cells at 24 h, was attenuated by 72 h by Beractant, but was never detected in Lucinactant cells.

<< Previous
Bronchoalveolar Lavage MMP-9 and TIMP-1 in Preschool Wheezers and...

Next >>
Relationship Between Functional Residual Capacity and Oxygen...